Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc., a company specializing in mental health treatments, for approximately $14.6 billion. The acquisition price is $132 per share, representing a 39% premium over the closing price on Friday. The deal marks a significant development in healthcare dealmaking following a slump in 2024. Intra-Cellular develops innovative treatments for central nervous system disorders, further expanding J&J’s portfolio of therapies under its umbrella.
Source: https://www.bloomberg.com/news/articles/2025-01-12/johnson-johnson-exploring-bid-for-intra-cellular